MNTN, Inc Class A (MNTN)
NYSE:MNTN
Want to see MNTN full AI Analyst Report?
Top Page
MNTN, Inc Class A
(NYSE:MNTN)
Select Model
Select Model
Rating:69Neutral
Price Target:
$9.50
▼(-5.57% Downside)
Action:Reiterated
Date:05/09/26
The score is driven primarily by improved financial fundamentals (profitability inflection and a debt-free balance sheet) and supportive earnings-call guidance for continued growth and EBITDA expansion. Offsetting this, technical indicators show a clear downtrend with weak momentum, and valuation is only moderately supportive with no dividend yield data.
Positive Factors
Balance sheet strength
The company’s debt-free balance sheet and rebuilt positive equity provide durable financial flexibility. With no leverage, MNTN can fund R&D, commercial expansion, or absorb short-term shocks without refinancing risk, improving its long-term resilience and strategic optionality.
Negative Factors
Weak free cash flow conversion
Although cash flow has turned positive, low FCF relative to net income suggests earnings are not fully converting to free cash. This limits internally available funds for expansion or M&A and leaves the company more reliant on disciplined working capital and execution to sustain investment without external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
The company’s debt-free balance sheet and rebuilt positive equity provide durable financial flexibility. With no leverage, MNTN can fund R&D, commercial expansion, or absorb short-term shocks without refinancing risk, improving its long-term resilience and strategic optionality.
Read all positive factors
MNTN, Inc Class A (MNTN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$595.83M
Dividend YieldN/A
Average Volume (3M)708.65K
Price to Earnings (P/E)18.6
Beta (1Y)1.14
Revenue Growth21.51%
EPS GrowthN/A
CountryUS
Employees499
SectorTechnology
Sector Strength88
IndustryAdvertising Agencies
Share Statistics
EPS (TTM)0.32
Shares Outstanding61,013,454
10 Day Avg. Volume1,086,425
30 Day Avg. Volume708,649
Financial Highlights & Ratios
PEG Ratio11.86
Price to Book (P/B)19.88
Price to Sales (P/S)20.95
P/FCF Ratio107.63
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue1.28
Enterprise Value/Gross Profit1.60
Enterprise Value/Ebitda6.28
Forecast
1Y Price Target
$20.14Price Target Upside100.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.96
Revenue Forecast (FY)$351.90M
MNTN, Inc Class A Business Overview & Revenue Model
Company Description
MNTN, Inc., a performance TV software company, provides performance advertising services in the United States. The company offers Performance TV software platform, enables marketers to target audiences through MNTN Matched technology and then dire...
How the Company Makes Money
null...
MNTN, Inc Class A Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
Overall the call conveyed solid top-line growth, expanding profitability, strong product adoption, and accelerated clinical trial progress — all meaningful positives. There are notable soft spots (a ~25% decline in MIS ablation, some international distributor weakness, modest sequential growth, and deliberate limits on SMB onboarding), but they appear manageable relative to the breadth of growth drivers and the company’s guidance for the year.Positive Updates
Strong Revenue Growth (Q1 2026)
Worldwide revenue of $141.2 million in Q1 2026, up 14.3% year-over-year (12.8% on a constant currency basis). U.S. revenue of $116.2 million, up 14.9% versus prior year; sequential revenue was roughly +1% versus Q4 2025.
Negative Updates
Decline in Minimally Invasive (MIS) Ablation Sales
U.S. minimally invasive (MIS) ablation sales declined approximately 25% year-over-year ($6.4 million), and the minimally invasive ablation franchise was described as facing headwinds in the quarter.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Revenue Growth (Q1 2026)
Worldwide revenue of $141.2 million in Q1 2026, up 14.3% year-over-year (12.8% on a constant currency basis). U.S. revenue of $116.2 million, up 14.9% versus prior year; sequential revenue was roughly +1% versus Q4 2025.
Read all positive updates
Company Guidance
Management guided Q2 revenue of $81–83 million (midpoint $82M, ~20% YoY) and full‑year revenue of $347–357 million (midpoint ~24% YoY), with adjusted EBITDA expected to be $96–101 million; this follows Q1 results of roughly $140–141.2M revenue (+14–14.3% YoY, +12.8% constant currency, ~+1% sequential) and $17M of adjusted EBITDA. Q1 U.S. revenue was $116.2M (+14.9%), including open ablation $39.1M (+17.3%), appendage management $48.4M (+14.9%, with AtriClip Flex Mini ≈40% of open appendage revenue), MIS ablation $6.4M (≈‑25%), and pain management $22.4M (+29.5%, Cryosphere Max Pro ≈70% of pain sales); international was $25M (+11.5% reported, +3.3% cc; Europe $16.1M +13.2%; Asia Pacific $8.9M +8.4%). Gross margin improved to 77.4% (+246 bps). Clinical and product timing guidance included BOX NOAF enrollment of ~300/960 patients to date with full enrollment expected around year‑end (nearly one year ahead) and CE Mark/launch plans for Flex Mini and Pro Mini later this year.MNTN, Inc Class A Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
84
Very Positive
Cash Flow
68
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 299.25M | 290.09M | 225.57M | 176.30M | 134.19M | 99.31M |
| Gross Profit | 239.28M | 221.31M | 161.52M | 123.41M | 72.42M | 65.97M |
| EBITDA | 60.80M | -2.65M | -11.83M | -25.28M | -76.18M | -15.18M |
| Net Income | 23.45M | -6.43M | -32.88M | -53.28M | -94.47M | -12.16M |
Balance Sheet | ||||||
| Total Assets | 375.12M | 378.30M | 238.74M | 194.80M | 203.40M | 249.14M |
| Cash, Cash Equivalents and Short-Term Investments | 213.90M | 210.16M | 82.56M | 54.97M | 50.91M | 97.03M |
| Total Debt | 0.00 | 0.00 | 50.25M | 49.33M | 53.55M | 48.62M |
| Total Liabilities | 56.49M | 72.57M | 346.34M | 300.71M | 291.36M | 280.67M |
| Stockholders Equity | 318.63M | 305.74M | -107.60M | -105.91M | -87.97M | -31.53M |
Cash Flow | ||||||
| Free Cash Flow | 19.56M | 56.47M | 32.60M | -3.05M | -61.02M | -5.02M |
| Operating Cash Flow | 61.61M | 56.47M | 42.55M | -3.05M | -56.95M | -1.10M |
| Investing Cash Flow | -17.54M | -17.11M | -9.95M | 37.79M | -4.07M | -1.36M |
| Financing Cash Flow | 87.56M | 88.24M | -5.00M | -34.88M | 14.90M | 91.71M |
MNTN, Inc Class A Risk Analysis
MNTN, Inc Class A disclosed 68 risk factors in its most recent earnings report. MNTN, Inc Class A reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Our development of proprietary AI Technologies is costly and complex, and we face significant risks related to technological challenges, competitive pressures, and dependence on third-party resources and data. Q1, 2026
MNTN, Inc Class A Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $688.77M | 23.32 | 23.85% | ― | 14.75% | ― | |
69 Neutral | $595.83M | 18.55 | 8.30% | ― | 21.51% | ― | |
69 Neutral | $1.87B | 96.63 | 18.57% | ― | 7.10% | 404.29% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
59 Neutral | $863.69M | 28.87 | 10.17% | ― | -0.43% | -15.84% | |
55 Neutral | $1.54B | -30.40 | 2.52% | ― | 4.48% | 868.83% | |
45 Neutral | $41.77M | -3.22 | -870.86% | ― | -24.54% | 42.74% |
* Technology Sector Average
MNTN
MNTN, Inc Class A
8.06
-19.65
-70.91%
STGW
Stagwell
6.22
1.46
30.67%
QNST
Quinstreet
11.99
-3.27
-21.43%
CRTO
Criteo SA
17.24
-9.25
-34.92%
MGNI
Magnite
13.06
-2.55
-16.31%
CDLX
Cardlytics
0.73
-1.17
-61.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.